UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Aerie Pharmaceuticals is implementing good security practices.
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
This report shows a preliminary security rating for Aerie Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
Defense in depth is a cyber security strategy that uses a series of layered, redundant defensive ...
Data is rapidly becoming one of the most valuable assets in the modern world. The digital giants ...
Compare Aerie Pharmaceuticals's security performance with other companies